However, many health outcomes, like nausea and vomiting, saw their risks increase with GLP-1 use. Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of ...

According to Dr Al-Aly’s team, careful monitoring of blood pressure and adjustment of antihypertensive medications may be needed. GLP-1 RA use also may reduce the risks for hepatic failure ...

Their findings published in Nature Medicine on Monday suggest that GLP-1 use is linked to beneficial ... Meanwhile, gastrointestinal disorders, low blood pressure, arthritis, and pancreatitis ...

A new study suggests that weight loss and diabetes treatment may represent only a small sample of the potential uses of GLP-1 drugs.

Employers face significant financial risk when investing in costly GLP-1 treatments, as employees who discontinue the medication without sustainable behavior changes may regain the weight ...

The uptake of GLP-1 has surged since 2022, mainly in US. Read our takeaways from the UBS Evidence Lab survey on key trends in GLP-1 consumer behaviour GLP-1s, also known as glucagon-like peptide 1, ...